FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to using lactitol in a therapeutically effective amount (1–20 g/day) for treating and preventing non-alcoholic fatty liver disease in a mammal.
EFFECT: invention provides a wider range of products for this therapy and prevention.
9 cl, 7 ex, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
| PREVENTIVE AND THERAPEUTIC DRUG FOR NON-ALCOHOLIC FATTY LIVER DISEASE | 2018 |
|
RU2820552C2 |
| NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| NOVEL PHARMACEUTICAL USE OF THIENO[3,2-D]PYRIMIDIN-4-ONE COMPOUNDS | 2019 |
|
RU2768828C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
| METHOD OF TREATING PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ON BACKGROUND OF METABOLIC SYNDROME | 2015 |
|
RU2595815C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| NEW APPLICATIONS AND METHODS | 2017 |
|
RU2765804C2 |
| METHOD OF PREDICTING THE EFFECTIVENESS OF LITHOLYSIS IN CHOLELITHIASIS IN COMBINATION WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2023 |
|
RU2813033C1 |
